Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669–676. ArticlePubMedCAS Google Scholar
Jones PF: Not just angiogenesis—wider roles for the angiopoietins. J Pathol 2003, 201:S15–S27. Google Scholar
Piccirillo JF, Tierney RM, Costas I, et al.: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441–2447. ArticlePubMedCAS Google Scholar
Schultz PN, Beck ML, Stava C, et al.: Health profiles in 5836 long-term cancer survivors. Int J Cancer 2003, 104:488–495. ArticlePubMedCAS Google Scholar
Morabito A, De Maio E, Di Maio M, et al.: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006, 11:753–764. ArticlePubMedCAS Google Scholar
Gerber HP, McMurtrey A, Kowalski J, et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/akt signal transduction pathway. J Biol Chem 1998, 273:30336–30343. ArticlePubMedCAS Google Scholar
Fan F, Wey JS, McCarty MF, et al.: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24:2647–2653. ArticlePubMedCAS Google Scholar
Shibuya M.: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006, 39:469–478. PubMedCAS Google Scholar
Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGF) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006, 42:3127–3139. ArticlePubMedCAS Google Scholar
Hurwitz H, Fehrenbacher L, Novony W, et al.: Bevacizum ab plus irinotecan, fluorouracil, leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342. ArticlePubMedCAS Google Scholar
Kabbinavar FF, Schulz J, McCleod M, et al.: Bevacizum ab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 [abstract]. J Clin Oncol 2004, 22(14S):3516. Google Scholar
Yang JC, Howarth L, Sherry RM, et al.: A randomized trial of bevacizum ab, an antivascular endothelial growth factor antibody, for metastatic renal cell carcinoma. N Engl J Med 2003, 349:427–434. ArticlePubMedCAS Google Scholar
Gordon MS, Cunningham D: Managing patients treated with bevacizum ab combination therapy. Oncology 2005, 69(Suppl 3):25–33. ArticlePubMedCAS Google Scholar
Chen HX, Mooney M, Boron M, et al.: Phase II multicenter trial of bevacizum ab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 2006, 24:3354–3360. ArticlePubMedCAS Google Scholar
Zhu AX, Blaszkowsky LS, Ryan DP, et al.: Phase II study of gemcitabine and oxaliplatin in combination with bevacizum ab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898–1903. ArticlePubMedCAS Google Scholar
Rugo HS, Herbst RS, Liu G, et al.: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005, 23:5474–5483. ArticlePubMedCAS Google Scholar
Inai T, Mancuso M, Hashizume H, et al.: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35–52. PubMedCAS Google Scholar
Sullivan JM, Prewitt RL, Josephs JA: Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension 1983, 5:844–851. PubMedCAS Google Scholar
Wickman G, Hallin M, Salansky KA, et al.: Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitum or activity [abstract]. Proc Am Assoc Cancer Res 2003, 44:865–865. Google Scholar
van Cruijsen H, Voest EE, van Herpen CML, et al.: Phase I clinical evaluation of AZD 2171 in combination with gefitinib, in patients with advanced tumors [abstract]. J Clin Oncol 2005, 23(Suppl):3030. Google Scholar
Sica DA: Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006, 24:1329–1330. ArticlePubMed Google Scholar
Veronese ML, Mosenkis A, Flaherty KT, et al.: Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006, 24:1363–1369. ArticlePubMedCAS Google Scholar
Thomas AL, Trarbach T, Bartel C, et al.: A phase IB, open label dose-escalating study of the oral amgiogenesis inhibitor PTK787/ZK 222585 (PTK/ZK), in combination with FOLFOX4 chem otherapy in patients with advanced colorectal cancer. Ann Oncol 2007, 18:782–788. ArticlePubMedCAS Google Scholar
Hecht JR, Trarbach T, Jaeger E, et al.: A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinom a of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract]. Proc Am Soc Clin Oncol 2005, 23:LBA3. Google Scholar
Favire S, Delbaldo C, Vera K, et al.: Safety, pharmacokinetic and antitum or activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25–35. ArticleCAS Google Scholar
Fiedler W, Serve H, Dohner H: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) not amenable to conventional therapy for the disease. Blood 2005, 100:986–993. Google Scholar
Holden SN, Eckhardt SG, Basser R, et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16:1391–1397. ArticlePubMedCAS Google Scholar
Hyder SM: Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Rel Cancer 2006, 13:667–687. ArticleCAS Google Scholar
Achard J: Protection against ischemia, a physiologic function of renin angiotensin system. Biochem Pharmacy 2001, 62:261–271. ArticleCAS Google Scholar
Silvestre JS, Bergaya S, Tamarat R, et al.: Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B (2) receptor pathway. Circ Res 2001, 89:678–683. PubMedCAS Google Scholar
Maitland M, Moshier K, Imperial J, et al.: Blood pressure (BP) as a biomarker for sorfanib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway [abstract]. J Clin Oncol 2006, 24(Suppl):2035. Google Scholar
Yeh ET: Cardiotoxicity induced by chem otherapy and antibody therapy. Annu Rev Med 2006, 57:485–498. ArticlePubMedCAS Google Scholar
Townsend RR: Hypertension and cancer chemotherapies. In Advanced Therapy in Hypertension and Vascular Disease. Edited by Mohler ER, Townsend RR. Toronto: BC Decker; 2006:502–507. Google Scholar
Mulcahy MF, Benson AB 3rd: Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005, 5:997–1005. ArticlePubMedCAS Google Scholar
Micha JP, Goldstein BH, Rettenmaier MA, et al.: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizum ab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007, In press.
National Cancer Institute: Common Toxicity Criteria version 2.0 (NIH CTC v2.0). Available at: http://ctep.cancer.gov/formsCTCv20_4-30-992.pdf. Look up under “CAR-DIOVASCULAR (GENERAL).” Accessed March 22, 2007.